Soluble notch receptor proproteins and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9644016-B2
Application number	US-201514673175-A
Country	US
Kind code	B2
Filing date	Mar 30, 2015
Priority date	Feb 23, 2009
Publication date	May 9, 2017
Grant date	May 9, 2017

Abstract

The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask. The disclosure further provides methods of screening for, making, and using these proproteins.

First claim

What is claimed is:

1. A composition comprising an activatable polypeptide comprising a functional protein that is not an antibody or an antibody fragment, wherein the functional protein is a soluble Notch receptor or fragment thereof, wherein the functional protein is coupled to a peptide mask that: (i) inhibits binding of the functional protein to its binding partner and (ii) does not have an amino acid sequence of the binding partner, and wherein the functional protein is further coupled to a cleavable linker, such that: (i) when the activatable polypeptide is in an uncleaved state, the peptide mask inhibits binding of the functional protein to its binding partner and (ii) when the activatable polypeptide is in a cleaved state, the peptide mask does not inhibit binding of the functional protein to its binding partner.

2. The composition of claim 1 , wherein the cleavable linker includes one or more substrates selected from the group consisting of: a sequence that is susceptible to specific cleavage by an enzyme, a bond that is susceptible to reductive cleavage by a reducing agent, and a bond that is susceptible to photolytic cleavage.

3. The composition of claim 1 , wherein the activatable polypeptide is recombinantly expressed.

4. The composition of claim 1 , wherein the peptide mask has one or more of the following characteristics: (i) the peptide mask is unique for the functional protein; (ii) the peptide mask has a therapeutic effect once uncoupled from the functional protein; (iii) the peptide mask is 8-15 amino acids in length; (iv) the peptide mask has less than 50% amino acid sequence homology to the natural binding partner of the functional protein; (v) the peptide mask contains less than 50% genetically non-encoded amino acids; (vi) the peptide mask contains less than 50% genetically non-encoded amino acids, wherein the genetically non-encoded amino acids are D-amino acids, β-amino acids, or γ-amino acids; (vii) the peptide mask inhibits binding of the functional protein to its binding partner allosterically; (viii) the peptide mask inhibits binding of the functional protein to its binding partner sterically; (ix) the binding affinity of the peptide mask to the functional protein is less than the binding affinity of the binding partner to the functional protein; (x) the dissociation constant (K d ) of the peptide mask towards the functional protein is at least 100 times greater than the K d of the functional protein towards its binding partner; or (xi) the K d of the peptide mask towards the functional protein is lower than about 5 nM.

5. The composition of claim 1 , wherein the peptide mask has one or more of the following characteristics: (i) the peptide mask inhibits the binding of the soluble receptor to its ligand; (ii) the peptide mask inhibits the soluble receptor's ligand binding domain; or (iii) the peptide mask contains a sequence selected from those presented in Table 14 or a sequence having at least 90% homology thereof.

6. The composition of claim 1 , wherein the Notch receptor is selected from the group consisting Notch1, Notch2, Notch3 and Notch4.

7. The composition of claim 5 , wherein the ligand is selected from the group consisting of DLL1, DLL3, DLL4, Jagged1, and Jagged2.

8. The composition of claim 1 , wherein the cleavable linker is a substrate for an enzyme selected from Table 2.

9. The composition of claim 1 , wherein the cleavable linker is a substrate for an enzyme selected from the group consisting of matriptase, plasmin, MMP-9, uPA, HCV-NS3/4, PSA, and legumain.

10. The composition of claim 9 , wherein a sequence for an MMP-9 substrate comprises VHMPLGFLGP (SEQ ID NO: 3).

11. The composition of claim 9 , wherein a sequence for a plasmin substrate comprises QGPMFKSLWD (SEQ ID NO: 4).

12. The composition of claim 1 further comprising an Fc region of an immunoglobulin.

13. The composition of claim 2 , wherein when the activatable polypeptide is not in the presence of an enzyme that cleaves the cleavable linker, the peptide mask inhibits the binding of the functional protein to its binding partner by at least 90% as compared to when the activatable polypeptide is in the presence of the enzyme that cleaves the cleavable linker and the peptide mask does not inhibit the binding of the functional protein to its binding partner.

14. The composition of claim 2 , wherein the cleavable linker is specifically cleaved by an enzyme at a rate of at least 5×10 4 M −1 s −1 .

15. A pharmaceutical composition, wherein said pharmaceutical composition comprises a therapeutically effective amount of a composition according to claim 1 and a pharmaceutically acceptable excipient.

16. A method of treating a disease or disorder, said method comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 15 .

17. The method of claim 16 , wherein the disease or disorder is cancer.

18. A method of inhibiting angiogenesis in a mammalian subject, said method comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of claim 15 .

19. The composition of claim 2 , wherein the enzyme is a protease.

20. The composition of claim 19 , wherein the protease is selected from the group consisting of: matriptase, plasmin, MMP-9, uPA, HCV-NS3/4, PSA, and legumain.

21. The composition of claim 1 , wherein the activatable polypeptide comprises at least one linker.

22. The composition of claim 21 , wherein at least one of the linkers is a glycine-serine rich linker.

23. The composition of claim 22 , wherein one or more of the glycine-serine rich linkers is selected from the group consisting of GQSGQ (SEQ ID NO: 88), GSSGGS (SEQ ID NO: 89), GGS (SEQ ID NO: 90), GGGSGGGSGGGSGGGSGGGSGGGS (SEQ ID NO: 91), and GG (SEQ ID NO: 92).

24. The composition of claim 21 , wherein the activatable polypeptide comprises at least one linker between the peptide mask and the functional protein.

25. The composition of claim 21 , wherein the activatable polypeptide comprises at least one linker between the cleavable linker and the peptide mask.

26. The composition of claim 21 , wherein the activatable polypeptide comprises at least one linker between the cleavable linker and the functional protein.

27. The composition of claim 21 , wherein the activatable polypeptide comprises at least one linker between the cleavable linker and the functional protein, and at least one linker between the cleavable linker and the peptide mask.

28. The composition of claim 21 , wherein the activatable polypeptide comprises an arrangement of the functional protein, the peptide mask, and the cleavable linker from N-terminus to C-terminus, wherein the arrangement is selected from the group consisting of: [peptide mask]-L1-[cleavable linker]-L2-[functional protein], and [functional protein]-L1-[cleavable linker]-L2-[peptide mask],
wherein L1 and L2 are linkers.

Assignees

• Cytomx Therapeutics Inc

Inventors

• Stagliano Nancy E
• West James W
• Kamath Kathryn
• Bessette Paul H
• Sagert Jason G

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61K47/65

  Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title